NASDAQ:GBTGlobal Blood Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Global Blood Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $60.51 -0.44 (-0.72 %) (As of 08/13/2020 10:54 AM ET) Add Compare Share Today's Range$58.76Now: $60.51▼$61.6150-Day Range$60.51MA: $68.72▼$74.4952-Week Range$39.95Now: $60.51▼$87.54Volume990,100 shsAverage Volume916,125 shsMarket Capitalization$3.71 billionP/E RatioN/ADividend YieldN/ABeta1.87 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingGlobal Blood Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.81, and is based on 17 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $105.95, Global Blood Therapeutics has a potential upside of 75.1% from its current price of $60.51.Amount of Analyst CoverageGlobal Blood Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesGlobal Blood Therapeutics has received 532 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGlobal Blood Therapeutics has received 344 “underperform” votes. (Add your “underperform” vote.)Community SentimentGlobal Blood Therapeutics has received 60.73% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote “Outperform” if you believe GBT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGlobal Blood Therapeutics does not currently pay a dividend.Dividend GrowthGlobal Blood Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Global Blood Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,682,317.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Global Blood Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Global Blood Therapeutics are expected to grow in the coming year, from ($3.91) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Global Blood Therapeutics is -12.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Global Blood Therapeutics is -12.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlobal Blood Therapeutics has a P/B Ratio of 6.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GBT Previous Symbol CUSIPN/A CIK1629137 Webwww.gbt.com Phone650-741-7700Debt Debt-to-Equity Ratio0.31 Current Ratio8.56 Quick Ratio8.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.11 million Price / Sales1,759.69 Cash FlowN/A Price / Cash FlowN/A Book Value$9.61 per share Price / Book6.30Profitability EPS (Most Recent Fiscal Year)($4.71) Net Income$-266,770,000.00 Net MarginsN/A Return on Equity-52.25% Return on Assets-39.47%Miscellaneous Employees171 Outstanding Shares61,361,000Market Cap$3.71 billion Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $60.51 -0.44 (-0.72 %) (As of 08/13/2020 10:54 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GBT News and Ratings via Email Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter. Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions How has Global Blood Therapeutics' stock been impacted by Coronavirus? Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GBT shares have increased by 10.3% and is now trading at $60.51. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Global Blood Therapeutics? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Global Blood Therapeutics. When is Global Blood Therapeutics' next earnings date? Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Global Blood Therapeutics. How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics Inc (NASDAQ:GBT) announced its earnings results on Wednesday, August, 5th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.18) by $0.32. View Global Blood Therapeutics' earnings history. What price target have analysts set for GBT? 21 brokerages have issued 1-year price targets for Global Blood Therapeutics' stock. Their forecasts range from $60.00 to $150.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $105.95 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price. View analysts' price targets for Global Blood Therapeutics. Has Global Blood Therapeutics been receiving favorable news coverage? News articles about GBT stock have been trending extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a news impact score of -4.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Global Blood Therapeutics. Who are some of Global Blood Therapeutics' key competitors? Some companies that are related to Global Blood Therapeutics include Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS) and ACADIA Pharmaceuticals (ACAD). View all competitors. What other stocks do shareholders of Global Blood Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Exelixis (EXEL), Cynosure (CYNO), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Square (SQ) and TherapeuticsMD (TXMD). Who are Global Blood Therapeutics' key executives? Global Blood Therapeutics' management team includes the following people: Dr. Ted W. Love, Pres, CEO & Director (Age 60)Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)Mr. Peter Radovich, Sr. VP of Operations (Age 41)Dr. Hing Sham, Sr. VP of Research (Age 67) When did Global Blood Therapeutics IPO? (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. What is Global Blood Therapeutics' stock symbol? Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT." Who are Global Blood Therapeutics' major shareholders? Global Blood Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include TimesSquare Capital Management LLC (2.07%), Goldman Sachs Group Inc. (1.00%), Bank of New York Mellon Corp (0.38%), Peregrine Capital Management LLC (0.34%), Fernwood Investment Management LLC (0.32%) and Botty Investors LLC (0.31%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown. View institutional ownership trends for Global Blood Therapeutics. Which institutional investors are selling Global Blood Therapeutics stock? GBT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State of Wisconsin Investment Board, Bank of New York Mellon Corp, Tekla Capital Management LLC, Russell Investments Group Ltd., Nicholas Investment Partners LP, American International Group Inc., and Alps Advisors Inc.. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Dawn Svoronos, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, and Tricia Borga Suvari. View insider buying and selling activity for Global Blood Therapeutics. Which institutional investors are buying Global Blood Therapeutics stock? GBT stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Asymmetry Capital Management L.P., CWM LLC, Frontier Capital Management Co. LLC, State Board of Administration of Florida Retirement System, New York State Common Retirement Fund, Ensign Peak Advisors Inc, and Candriam Luxembourg S.C.A.. View insider buying and selling activity for Global Blood Therapeutics. How do I buy shares of Global Blood Therapeutics? Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Global Blood Therapeutics' stock price today? One share of GBT stock can currently be purchased for approximately $60.51. How big of a company is Global Blood Therapeutics? Global Blood Therapeutics has a market capitalization of $3.71 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe. What is Global Blood Therapeutics' official website? The official website for Global Blood Therapeutics is www.gbt.com. How can I contact Global Blood Therapeutics? Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
